6 minutes | Feb 15th 2019

FDA weighs esketamine for depression

Contact us: podcasts@mdedge.com

  1. FDA panels back intranasal esketamine for refractory depression. http://bit.ly/2TOKrfp
  2. ONC aims to help doctors, patients with information sharing in proposed rule. http://bit.ly/2X3SVkP
  3. Survey: Health care costs unlikely to improve in 2019. http://bit.ly/2SwSIYJ
  4. Vaccination and antiviral treatment don't lower stroke risk after shingles. http://bit.ly/2tjYQVa
Play
Like
Play Next
Mark Played